GLP-1s Are Only the Beginning: What the Next Generation of Obesity Medications Could Mean for Weight Loss, Muscle, and Long-Term Health

Introduction

A few years ago, most people had never heard of GLP-1 medications. Now, names like Ozempic, Wegovy, Mounjaro, and Zepbound are part of everyday conversation.

That shift happened fast.

These medications have changed what many people thought was possible for obesity treatment. For some, they have helped produce levels of weight loss once associated mostly with bariatric surgery. They have also helped more people understand that obesity is not simply a “try harder” problem. Appetite, hunger, fullness, blood sugar regulation, hormones, brain signaling, environment, genetics, sleep, stress, and behavior all interact.

But GLP-1 medications are not magic. They have limits.

Weight loss often slows or plateaus around 18 months. Some people regain a meaningful amount of weight after stopping the medication. Some people respond very well, while others respond only modestly or barely at all. Side effects, cost, access, insurance coverage, and long-term use also matter.

A recent narrative review looked at the next wave of obesity medications and where the field may be heading. Instead of treating GLP-1s as the final answer, the review presents them as the beginning of a much larger shift in obesity pharmacotherapy.

The future may involve pills instead of injections, medications that target multiple hormone pathways at once, drugs that focus more directly on fat loss and liver fat, and even treatments designed to preserve or increase lean mass while reducing body fat.

That does not mean everyone should take these medications. It also does not mean lifestyle habits suddenly stop mattering.

It means the conversation is changing.

What the Science Says

The review by Lempesis and Dalamaga was a narrative review, meaning the researchers did not run a new trial. Instead, they synthesized existing clinical trials, systematic reviews, and consensus guidelines to summarize where obesity medication is now and where it appears to be going.

The main focus was a comparison of medications in development or already available: how they work, what pathways they target, how much weight loss they tend to produce, and which groups of people may benefit most.

The current best-known GLP-1 medication is semaglutide, sold under names like Ozempic and Wegovy. GLP-1 receptor agonists work partly by reducing appetite, slowing digestion, and helping people feel full with less food.

Tirzepatide, sold as Mounjaro and Zepbound, goes a step further by acting on both GLP-1 and GIP receptors.

But the next generation of medications is expanding beyond those pathways.

Oral semaglutide and orforglipron: GLP-1s in pill form

Most GLP-1 medications are weekly injections. They also often require refrigeration, which can make them harder and more expensive to manufacture, store, ship, and distribute.

Oral semaglutide, sold as Rybelsus, already exists as a pill, but it has specific timing rules. It must be taken 30 minutes before eating or drinking anything other than a small amount of water.

Orforglipron is different. It is a small-molecule GLP-1 medication, meaning it behaves more like a traditional pill. It does not require the same food timing restrictions or refrigeration.

That may matter a lot.

The early data suggest orforglipron can produce roughly 10–15 percent average weight loss, depending on dose and duration. That is not necessarily more impressive than the strongest injectable options, but its biggest advantage may be access and convenience. A daily pill that does not require refrigeration could reach more people, especially in areas where injectable drugs are harder to distribute.

For some people, the idea of taking a pill may also feel less intimidating than starting an injectable medication.

Retatrutide: the triple agonist

Retatrutide is one of the more striking drugs in the pipeline because it targets three hormone receptors at once: GLP-1, GIP, and glucagon.

GLP-1 helps suppress appetite and slow digestion. GIP appears to influence insulin secretion and nutrient handling. Glucagon may increase energy expenditure and support liver fat metabolism.

In trials, retatrutide produced weight loss of about 20–24 percent at 48 weeks. That is approaching the range seen with bariatric surgery, which is why this medication has drawn so much attention.

That does not mean it is the right answer for everyone. It does suggest that multi-receptor drugs may become a major part of obesity treatment going forward.

Survodutide and mazdutide: GLP-1 plus glucagon

Survodutide and mazdutide are dual agonists that combine GLP-1 activity with glucagon receptor activity. The basic idea is to reduce appetite while also increasing fat burning and energy expenditure.

Survodutide produced weight loss of up to about 15 percent at 46 weeks. It also reduced liver fat by at least 30 percent at 48 weeks, making it especially interesting for people with metabolic dysfunction-associated steatotic liver disease, or MASLD.

Mazdutide produced around 14 percent weight loss at 48 weeks, with some higher-dose groups reaching up to 21 percent at 20 weeks.

This is one place where the future of obesity medication may become more personalized. Some medications may be especially useful for people whose obesity is tied closely to liver fat, blood sugar regulation, or other metabolic complications.

Maridebart cafraglutide: the once-monthly option

Maridebart cafraglutide, also called MariTide, takes a different approach. It combines GLP-1 receptor activation with GIP receptor antagonism, meaning it activates one pathway while blocking another.

That sounds odd because tirzepatide activates both GLP-1 and GIP receptors.

Apparently, both approaches may work, though likely through different mechanisms.

One of the biggest practical advantages is dosing. MariTide has a longer half-life, allowing for once-monthly use.

In trials, it produced up to 16–20 percent weight loss at 52 weeks, with no plateau observed during the study period.

That “no plateau” detail is interesting, but it needs caution. It does not mean weight loss would continue indefinitely. It means that during the trial window, weight loss had not clearly leveled off yet.

Cagrilintide, eloralintide, and amycretin: targeting amylin

Not every new obesity medication is built around GLP-1.

Some target amylin, a hormone released by the pancreas along with insulin after meals.

Amylin helps regulate satiety, reduce meal size, and slow digestion.

Cagrilintide produced about 6–11 percent weight loss at 26 weeks.

Eloralintide produced up to approximately 20 percent weight loss at 48 weeks.

CagriSema, which combines cagrilintide with semaglutide, produced about 14–20 percent weight loss at 68 weeks, with HbA1c reductions of up to 2 percent.

Amycretin, which activates both GLP-1 and amylin receptors, produced up to 24 percent weight loss at 36 weeks in an early-phase trial, with no plateau observed.

Again, early-phase results should not be treated as final proof. But they show that the field is moving beyond one single pathway. Appetite, fullness, blood sugar, digestion, fat storage, fat burning, and body composition may all become medication targets.

Bimagrumab: focusing on muscle and fat mass

Bimagrumab may be one of the most interesting drugs because it is not primarily an appetite-suppressing medication.

Instead, it blocks activin type II receptors, which may promote muscle growth while reducing fat mass.

On its own, bimagrumab produced modest overall weight loss, up to about 6.5 percent.

But the body composition changes were more impressive: around a 20 percent reduction in fat mass and a 4 percent gain in lean mass at 48 weeks.

When combined with semaglutide, bimagrumab produced up to 22 percent weight loss at 72 weeks, with nearly 93 percent of that weight loss coming from fat.

That is a big deal because standard GLP-1 therapy often produces weight loss that includes both fat and lean mass. Losing body weight is not the only goal. Ideally, a person wants to lose mostly fat while preserving as much muscle and functional strength as possible.

This points toward a future where obesity treatment may focus less on simply lowering the number on the scale and more on improving body composition, function, and long-term health.

What This Means in Real Life

The biggest takeaway is that obesity treatment is becoming more advanced, more targeted, and potentially more individualized.

For decades, weight loss advice was often reduced to “eat less and move more.” That advice contains a piece of truth, but it is incomplete. Human appetite and body weight regulation are more complex than a motivational slogan.

These medications show that biology matters.

When hunger decreases, fullness improves, food noise quiets down, and blood sugar regulation changes, many people can finally do the habits they were previously told to just “try harder” at doing.

At the same time, medication does not remove the need for good health habits.

This is where people can overcorrect.

One bad interpretation is: “These drugs are cheating.”

That misses the point. Obesity is a real medical condition, and effective treatment should not be dismissed just because it involves medication.

Another bad interpretation is: “These drugs replace nutrition and exercise.”

That also misses the point. Food quality, protein intake, resistance training, sleep, stress management, and long-term behavior still matter, especially when appetite is reduced.

If someone eats very little because the medication suppresses appetite, they may lose weight quickly but also under-eat protein, micronutrients, and total energy. That can contribute to fatigue, weakness, digestive issues, and loss of lean mass.

The review notes warning signs that weight loss may be too aggressive, including losing more than 5 percent of body weight per month, BMI dropping below 18.5, eating below 800 calories per day, noticeable weakness, or difficulty with daily tasks.

That is important because more weight loss is not always better.

For many people with obesity, losing 5 percent of body weight can improve blood pressure, blood sugar, and cholesterol. Losing 10 percent may be needed for more meaningful improvements in liver fat and sleep apnea. Losses beyond 15 percent may further improve quality of life and health risk for some people.

But the goal is not to become as small as possible.

The goal is better health, better function, better metabolic markers, less pain, more energy, and a life that feels more livable.

That means the basics still matter.

Protein matters because it supports muscle retention, recovery, immune function, and satiety. The paper referenced a recommendation of at least 1.3 grams of protein per kilogram of body weight per day for people using GLP-1 therapy.

Resistance training matters because protein alone is not enough to preserve lean mass during weight loss. Lifting weights gives the body a reason to keep muscle.

Strength matters because the goal is not just a lower weight. The goal is being able to carry groceries, climb stairs, get off the floor, travel, play with kids or grandkids, age well, and maintain independence.

Medication can make weight loss easier. It does not automatically build a strong, capable body.

Practical Takeaways

If you are taking or considering one of these medications, the first step is to work with a qualified medical provider. These are real medications with real effects, real benefits, and real risks.

From there, the practical foundation is fairly straightforward.

Pay attention to how fast weight is coming off. Rapid weight loss may feel exciting at first, but faster is not always better if energy, strength, digestion, or nutrition quality are falling apart.

Prioritize protein even when you are not very hungry. Appetite suppression can make it surprisingly easy to under-eat. Protein shakes, Greek yogurt, cottage cheese, eggs, lean meats, fish, tofu, beans, and other protein-rich foods can help.

Strength train at least twice per week if you are able. The point is not to “burn calories.”

The point is to preserve muscle, maintain function, support metabolism, and help shape the weight you lose.

Watch for signs that your plan is too aggressive: persistent fatigue, dizziness, weakness, feeling unable to complete normal daily tasks, losing strength quickly, or struggling to eat enough.

Do not treat medication as a substitute for sleep, stress management, movement, or food quality. It can be a powerful tool, but it works best inside a larger health-supporting routine.

Be careful with scale obsession. The next generation of medications may improve body composition in ways the scale does not fully capture. Measurements, strength, energy, bloodwork, waist circumference, fitness, and daily function can all matter.

And finally, avoid turning this into a moral issue.

Taking medication does not make someone weak. Not taking medication does not make someone superior. Losing weight with help still counts. Choosing not to pursue weight loss medication can also be a valid decision.

Context matters.

Closing Thoughts From Two Decades of Coaching

After working with people for a long time, one thing becomes obvious: weight loss is rarely just about knowing what to do.

Most people already know the basics. They know vegetables are useful. They know protein matters. They know walking helps. They know sleep matters. They know strength training is good for them.

The hard part is doing those things consistently while living a real life.

Stress changes appetite. Poor sleep changes cravings. Pain changes movement. Work changes time. Family obligations change routines. Depression, anxiety, medications, hormones, injuries, and financial pressure all shape behavior.

That is why these medications are so important. They are not a replacement for personal responsibility, but they can reduce some of the biological resistance that makes change feel nearly impossible for some people.

At the same time, the most successful long-term approach still has to respect the whole person.

A lower body weight without strength, energy, nourishment, and peace around food is not the finish line. A good plan should help someone live better, not just weigh less.

The future of obesity medicine looks promising. Pills may improve access. Multi-receptor medications may produce stronger outcomes. Amylin-based drugs may give providers new tools. Muscle-preserving treatments may shift the focus from weight loss alone to healthier body composition.

That is all encouraging.

But the foundation remains the same: use the best tools available, apply them wisely, and build habits that support the life you actually want to live.

Medication may open the door.

Your daily behaviors still determine what kind of life you build on the other side of it.

References

Lempesis IG, Dalamaga M. “Obesity pharmacotherapy reimagined: The era of multi-receptor agonists and next-generation metabolic modulators, perspectives and controversies.” Metabolism Open. 2026;30:100463.

Horn DB, Ryan DH, Kis SG, et al. “Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2).” Lancet. 2026;406:2927–44.

Frias JP, Hsia S, Eyde S, et al. “Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study.” Lancet. 2023;402:472–83.

Celletti F, Farrar J, De Regil L. “World Health Organization guideline on the use and indications of glucagon-like peptide-1 therapies for the treatment of obesity in adults.” JAMA. 2026;335:434–8.

Jastreboff AM, Kaplan LM, Frías JP, et al. “Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial.” N Engl J Med. 2023;389:514–26.

le Roux CW, Steen O, Lucas KJ, et al. “Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial.” Lancet Diabetes Endocrinol. 2024;12:162–73.

Sanyal AJ, Bedossa P, Fraessdorf M, et al. “A phase 2 randomized trial of survodutide in MASH and fibrosis.” N Engl J Med. 2024;391:311–9.

Ji L, Jiang H, Bi Y, et al. “Once-weekly mazdutide in Chinese adults with obesity or overweight.” N Engl J Med. 2025;392:2215–25.

Bhattachar SN, Tham LS, Li Y, et al. “Mazdutide reduces body weight in adults with overweight or obesity: a high-dose phase 1 trial.” Diabetes Obes Metab. 2025;27:6460–9.

Jastreboff AM, Ryan DH, Bays HE, et al. “Once-monthly maridebart cafraglutide for the treatment of obesity — a phase 2 trial.” N Engl J Med. 2025;393:843–57.

Lau DCW, Erichsen L, Francisco AM, et al. “Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.” Lancet. 2021;398:2160–72.

Billings LK, Hsia S, Bays H, et al. “Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial.” Lancet. 2025;406:2631–43.

Garvey WT, Blüher M, Osorto Contreras CK, et al. “Coadministered cagrilintide and semaglutide in adults with overweight or obesity.” N Engl J Med. 2025;393:635–47.

Davies MJ, Bajaj HS, Broholm C, et al. “Cagrilintide-semaglutide in adults with overweight or obesity and type 2 diabetes.” N Engl J Med. 2025;393:648–59.

Dahl K, Toubro S, Dey S, et al. “Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study.” Lancet. 2025;406:149–62.

Heymsfield SB, Coleman LA, Miller R, et al. “Effect of bimagrumab vs placebo on body fat mass among adults with type 2 diabetes and obesity: a phase 2 randomized clinical trial.” JAMA Netw Open. 2021;4:e2033457.

Mozaffarian D, Agarwal M, Aggarwal M, et al. “Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society.” Obesity. 2025;33:1475–503.

Calls to Action

Want help building a realistic plan for nutrition, strength training, sleep, stress, and long-term consistency? Apply for coaching and we’ll look at what actually fits your life.

Want more practical research reviews like this? Join the mailing list and get them sent directly to your inbox.